Orient Bio

Orient Bio Capital Intensity

The Capital Intensity Ratio of Orient Bio (002630.KS) as of Oct 21, 2026 is 274.30 %. In the previous year, Capital Intensity Ratio was 288.39 % — a change of -4.89% (lower).

Capital Intensity

274.30 %

YoY

-4.89%

Last updated:

Capital Intensity Ratio of Orient Bio is 2026 274.30 % . Capital Intensity Ratio of Orient Bio was 2025 288.39 % . It decreases by -4.89% lower compared to the previous year.

The Orient Bio Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2019
276.85 KRW
Jan 1, 2020
191.26 KRW
Jan 1, 2021
137.48 KRW
Jan 1, 2022
399.41 KRW
Jan 1, 2023
281.24 KRW
Jan 1, 2024
346.32 KRW
Jan 1, 2025
288.39 KRW
Jan 1, 2026
274.30 KRW
The Orient Bio Capital Intensity history
YEARCapital IntensityYoY
274.30 %-4.89%
288.39 %-16.73%
346.32 %+23.14%
281.24 %-29.59%
399.41 %+190.52%
137.48 %-28.12%
191.26 %-30.91%
276.85 %+76.58%
156.78 %-0.99%
158.34 %-5.30%
167.20 %+5.32%
158.75 %-4.81%
166.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Capital Intensity Ratio of Orient Bio is 274.30 % in 2026.

Capital Intensity Ratio of Orient Bio changed from 288.39 % to 274.30 %, representing a -4.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Orient Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Orient Bio

All Key Metrics — Orient Bio